Combination of Temsirolimus and Bevacizumab in Patient With Metastatic Renal Cell Carcinoma
Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
The TORAVA trial is designed to evaluate the progression-free rate at 48 weeks of a
combination of Torisel® and Avastin® given at first-line treatment in patients with
metastatic renal cancer.
Eligible patients will be randomly assigned, in a 2:1:1 ratio, to either Avastin® + Torisel®,
or Sutent® or IFN+Avastin®.